-+ 0.00%
-+ 0.00%
-+ 0.00%

Eisai plans to present five-year lecanemab study data at CTAD conference

PUBT·10/29/2026 11:07:09
Listen to the news
Eisai plans to present five-year lecanemab study data at CTAD conference
  • Eisai will present five-year lecanemab data at the Clinical Trials on Alzheimer's Disease conference in Boston and online, November 16-19, 2026.
  • The Clarity AD presentation on November 16 will examine long-term treatment outcomes for the Alzheimer's drug, marketed as Leqembi.
  • A November 18 symposium will examine real-world treatment outcomes from LEADER, a retrospective study across diverse US clinical settings.
  • Additional presentations will address real-world safety, treatment persistence and subcutaneous administration.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eisai Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610290700PR_NEWS_USPR_____NY83861) on October 29, 2026, and is solely responsible for the information contained therein.